Immune checkpoint inhibitors are revolutionizing the treatment algorithm for the unresectable locally advanced or metastatic bladder cancer. With the 2016/7 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients (i.e., second– and later lines), PD-L1 inhibitor Tecentriq (Roche/Genentech) first followed by PD-1 inhibitor Opdivo (Bristol-Myers Squibb) and other PD-1/PD-L1 inhibitors, significant sales are forecast to be generated in the unresectable locally advanced or metastatic setting. There is now intense phase II/III pipeline activity, with some drugs in late-phase pipeline also targeting previously-untreated unresectable locally advanced or metastatic bladder cancer (i.e., first-line setting). We anticipate that several new therapies will gain approvals within the forecast period, resulting in increased therapy options for patients.
How large are the clinically and commercially relevant drug-treatable unresectable locally advanced or metastatic bladder cancer populations and how will drug-treatment rates change over time?
What is the current state of treatment for unresectable locally advanced or metastatic bladder cancer?
What are the (dis)advantages of currently marketed drugs and interviewed experts’ insights on these therapies?
What clinical needs remain unfulfilled and what opportunities can developers capitalize on?
What pipeline products are most promising, and what sales/uptake could they secure in the unresectable locally advanced or metastatic bladder cancer market?
What are the most promising early-phase pipeline products?
What are the drivers and constraints in the unresectable bladder cancer market, and how will the market evolve over the 10-year forecast period within the major markets?
Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.